BIOEN Biotrend Cevre ve Enerji Yatirimlari A.S.
Biotrend Cevre ve Enerji Yatirimlari A.S. engages in integrated waste management-oriented renewable energy, circular raw materials, and fuel production activities in Turkey. It is involved in the waste disposal; mechanical sorting; recycled products; refuse-derived fuel; generation of electricity and heat from biogas, landfill gas, and biomass; carbon trading; composting; sanitary landfills; and greenhouse farming. The company also engages in production of energy using fermentation, incineration technologies; operation of solid waste storage areas, mechanical separation plant, waste derived fuel preparation plant, leachate treatment plant, biological treatment plant, and landfill gas; and installation and operation of power generation plants, as well as provision of engineering, contracting, and consulting services. The company was founded in 2017 and is headquartered in Istanbul, Turkey. Biotrend Cevre ve Enerji Yatirimlari A.S. operates as a subsidiary of Doganlar Investment Holding A.S.…
Industry Peers
Utilities - RenewableKey Statistics
About Biotrend Cevre ve Enerji Yatirimlari A.S. (IST: BIOEN)
›
Biotrend Cevre ve Enerji Yatirimlari A.S. (IST: BIOEN) is listed on Borsa Istanbul, where its shares trade in TRY. It belongs to the Utilities - Renewable industry, part of the Utilities sector, and reports about 824 employees.
The shares were at 14.26 TRY on 20 November 2026, down 27.7% over 52 weeks. Its 52-week range is 9.000 TRY to 22.48 TRY: the price is 36.6% below the high and 58.4% above the low.
At a market capitalisation of 7.22B TRY, it trades at 3.8 times trailing earnings. The median trailing P/E of its 14 largest Utilities - Renewable peers is 28.5, a discount of 87% for BIOEN.
Biotrend Cevre ve Enerji Yatirimlari A.S. reports return on equity of -49.6%, an operating margin of -34.7% and revenue up 31.3% year over year.
Its debt exceeds its cash by 6.60B TRY, a debt-to-equity ratio of 1.86. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. One analyst covers the stock; their mean price target of 22.00 TRY is 54.3% above the current price.